Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment
January 05, 2017
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Re...
Read more
